<DOC>
	<DOCNO>NCT02013531</DOCNO>
	<brief_summary>The purpose study investigate efficacy safety flexibly dose adjunctive brexpiprazole treatment subject major depressive disorder anxiety symptom , experience inadequate selective serotonin reuptake inhibitor ( SSRI ) /serotonin norepinephrine reuptake inhibitor ( SNRI ) response .</brief_summary>
	<brief_title>Brexpiprazole ( OPC-34712 ) Adjunctive Treatment Adults With Major Depressive Disorder Anxiety Symptoms</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Brexpiprazole</mesh_term>
	<criteria>Main Have diagnosis single recurrent , nonpsychotic episode MDD define Diagnostic Statistical Manual Mental Disorders , Fourth Edition , Text Revision ( DSMIVTR ) confirm Mini International Neuropsychiatric Interview ( M.I.N.I . ) adequate clinical psychiatric evaluation . Have treatment history inadequate ADT response least 1 ADT ( &gt; 3 ) current episode . Have receive single , trialapproved , SSRI SNRI adequate dose ≥ 6 week prior screen . Are 18 65 year old time consent ( inclusive , outpatient ) . Have Hamilton Depression Rating Scale ( HAMD ) 17item Total Score ≥ 18 screen baseline . Have Hamilton Anxiety Rating Scale ( HAMA ) Total Score ≥ 20 screen baseline . Main Subjects follow current Axis I DSMIVTR diagnosis : delirium dementia amnestic cognitive disorder schizophrenia schizoaffective disorder psychotic disorder bipolar I disorder , bipolar II disorder bipolar disorder otherwise specify ( NOS ) eat disorder anorexia nervosa bulimia obsessive compulsive disorder posttraumatic stress disorder Subjects follow current Axis II DSMIVTR diagnosis : borderline , antisocial paranoid schizoid schizotypal histrionic personality disorder mental retardation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>Major depressive disorder</keyword>
	<keyword>Anxiety Symptoms</keyword>
	<keyword>Mental Disorders</keyword>
	<keyword>Psychotic Disorders</keyword>
	<keyword>emotional withdrawal</keyword>
	<keyword>antipsychotic</keyword>
</DOC>